REMAP Therapeutics的封面图片
REMAP Therapeutics

REMAP Therapeutics

健康与健身服务

New York,New York 363 位关注者

Exploring and innovating the intersection between psychedelics and chronic pain.

关于我们

Exploring, innovating, and developing the intersection between chronic pain and psychedelics.

网站
https://remaptherapeutics.com
所属行业
健康与健身服务
规模
2-10 人
总部
New York,New York
类型
合营企业
创立
2020
领域
rehabilitation、chronic pain、physiotherapy 、psychedelics和Applied neurop

地点

REMAP Therapeutics员工

动态

  • Wonderful to see the PTSD-relieving effects of psilocybin being given fuller investigation for this population. We documented significant changes in CAPS scores for this condition in our case-study of treating CRPS with psilocybin and know this to be true within the cluster headache community as well.

    查看Tammy Le的档案

    The Heroic Hearts Project, Psychedelic Therapy and Mental Health Advocate for US Veterans

    Dr. Lynnette A. Averill, PhD Averill and Baylor College of Medicine are thrilled to be initiating enrollment for a Texas state-funded trial of psilocybin-assisted therapy for #Veterans with PTSD. This study is supported by HB1802, which passed with nearly unanimous support in the Texas House and Senate and was landmark legislation. The study will trial two doses of psilocybin delivered with supportive therapy before (preparation sessions), during and after (integration sessions) dosing. #Psilocybin is currently a DEA-classed Schedule 1 drug and experimental treatment with Breakthrough Therapy status through the FDA. Consequently, there are carefully considered eligibility criteria for participation to help ensure safety. If you are interested in learning more, please scan the QR code with your phone to complete a brief pre-screening questionnaire. You can also contact our study team at?[email protected]?to have the link sent to you. ?

    • 该图片无替代文字
  • REMAP Therapeutics转发了

    查看Psychedelics Today的组织主页

    20,971 位关注者

    Prohibition Hinders Crucial Scientific Research Discover the hidden challenges scientists face when researching prohibited substances. This documentary explores the impact of prohibition on scientific advancement, highlighting crucial examples like ibogaine and bufotinine, substances with potential medical benefits that remain largely unknown due to legal restrictions. Learn why unrestricted research is vital for scientific progress. #ScientificResearch #Prohibition #SubstanceUseDisorder #Ibogaine #Bufotinine #DrugPolicy #MedicalResearch #ScienceDocumentary #HiddenScience #ResearchChallenges

  • REMAP Therapeutics转发了

    查看Josh Hardman的档案

    Founder at Psychedelic Alpha - Commentary, Consultancy, Community for the psychedelics industry

    Less than a week into 2025, both APAs—the American Psychiatric Association and the American Psychological Association—have put psychedelic research and roll-out preparedness firmly on the map, with the former publishing a special issue of the American Journal of Psychiatry solely dedicated to psychedelics, and the latter announcing (via its Emerging Trends report) a series of webinars and a toolkit to be published this year. While 2024 might be remembered as the year that psychedelic research and therapy was called into question by incumbents, then, 2025 might go down as the year that those same incumbents came to the table in earnest to attempt to understand and engage with the field more meaningfully. In my latest at Psychedelic Alpha, I read through the 132-page journal issue and summarise it for our readers. If you're part of the 'psychedelics field', much of the ground covered in this special issue will be familiar territory. But what this does provide is an excellent overview for the broader psychiatry community, backed by the imprimatur of APA. That might encourage the broader field of psychiatry and related areas to learn more about psychedelics research, especially given the fact that some of the issue’s content has CME credit attached. What’s more, the issue’s very existence should lend credibility to the field, as well as the specific future research and roll-out preparedness directions identified in its contributions. While the majority of the authors who contributed to the issue are based in the U.S.—from Austin to Albuquerque—there is representation from Canada, Portugal, the Netherlands, and the UK. The journal’s readership, and thus reach, is international, too. As such, while the content may offer little in the way of fresh insight for the psychedelics field itself, it provides an excellent overview and visibility of its work to date that many hope will attract further interest from broader fields. Link in the comments.

    • 该图片无替代文字
  • REMAP Therapeutics转发了

    查看Joe Moore的档案

    CEO at Psychedelics Today

    I hope META will stop censoring Psychedelics Today. It has certainly hurt us quite a bit in the last year. Consider buying some of our classes or becoming a part of our Navigator program! www.psychedelicstoday.com

    查看Steven Bartlett的档案
    Steven Bartlett Steven Bartlett是领英影响力人物

    Founder: FlightStory, Thirdweb, The Diary Of A CEO

    This is one of the most important videos you’ll see on the internet this year ?? Zuckerberg says Facebook & Instagram will now prioritise free speech ?? This is a cultural tipping point that will have knock on effects for the rest of the internet ? Mark says "fact checkers" were too biased & legacy media too political about censorship ??? We're entering a new era of social media called "freedom of expression" My thoughts? Obviously this has been influenced by Trump and Elon, however: ?? As Tim Urban's book "What's our problem" highlights, good ideas, when taken to an extreme or followed in sequence, can lead to unintended bad outcomes. This applies profoundly to online censorship: Societies often embrace a good idea like: “protect individuals from harm.” But if this idea is prioritised *above all else* it can spiral into overreach: The sequence might look like this: 1?? Start with a noble goal: Censorship to reduce hate speech, misinformation, or harassment 2?? The scope expands: The definition of “harm” broadens to include ideas that offend, make people uncomfortable or that people disagree with 3?? Silence dissent: Legitimate debate & differing opinions are suppressed, creating an echo chamber of “approved” ideas. (See the middle ages where the church controlled truth & dissenters were murdered) 4?? Erode trust: People lose faith in platforms they once trusted to facilitate open dialogue, seeing them as the "thought police" ?? This is exactly what happened this decade Platforms like Meta, X & YouTube initially embraced "free speech" but faced extreme pressure to moderate & history shows that the pendulum often swings too far, leading to: ??Perceived Bias: Users believe platforms favour certain ideologies or narratives, damaging trust ??Polarisation: Perceived over-censorship leads to silos where people retreat to echo chambers (many more major social networks now than 10 years ago) ??Chilling Effects: Fear of backlash, bans or being cancelled, discourages genuine conversation, undermining the original goal of protecting free expression ? Balancing competing values is critical, which means there is NO PERFECT SOLUTION. The correct answer will therefore annoy all sides: Platforms must protect users without stifling conversation. How? 1?? Be Transparent: Clear, consistent moderation policies that everyone can see, that protect people against incited violence, real harm & illegal activity 2?? Decentralise "truth": Features like Community Notes decentralise decision-making and allow users to fact-check / add context in public view. No media organisation or person should be the truth police 3?? Defend Core Principles: Protect free expression (from all sides) as the cornerstone of a healthy online society, even when it’s uncomfortable, pisses you off or offends you 4?? User Empowerment: Give users more control on the algorithm they use and what they want to consume. Thoughts?

  • Boris is the best; congrats..!

    查看Webdelics的组织主页

    382 位关注者

    Huge congratulations to Dr. Boris Heifets, MD, Ph.D. on being nominated for the Webdelics' Top 25 Emerging Leaders in Psychedelic Research and Modern Theory. Dr. Boris Heifets is an assistant professor in Anesthesiology & Perioperative Medicine at Stanford, with a background in neuroscience from Yale and an M.D./Ph.D. from Albert Einstein College of Medicine. His research focuses on rapid-acting treatments for psychiatric diseases, including ketamine, MDMA, and psilocybin, and their integration into perioperative care. Known for uncovering MDMA's prosocial effects in mice and leading a ketamine trial in anesthetized patients, Dr. Heifets bridges neuroscience and clinical practice. His work is shaping the use of psychedelics in psychiatric and perioperative medicine, marking him as a leader in the field. Check out the full list here:https://lnkd.in/g-Wj92zH

    • 该图片无替代文字
  • REMAP Therapeutics转发了

    For anyone suffering from postpartum depression, please check out this trial. Good maternal mental health sets the foundation for a family. A happy, healthy mama makes happy, healthy kids.

    查看Sunstone Therapies的组织主页

    2,334 位关注者

    Explore a new investigational treatment option for #postpartum depression at Sunstone. Learn if participating in a research study is an option for you. Compensation Included. See if this trial is right for you : https://lnkd.in/e2GpRy7u

    • 该图片无替代文字
  • REMAP Therapeutics转发了

    查看Tommaso Barba的档案

    PhD candidate at Centre for Psychedelic Research, Imperial College London

    Is the power of #psychedelics in the substance itself, or does human #connection enhance their effects? ?? Recent research highlights the vital role of the therapeutic alliance in psilocybin-assisted therapy. ?? The study found that a stronger alliance between participants and facilitators, characterized by trust, collaboration, and emotional attunement, as directly associated with greater reductions in depression. ?? Participants with stronger alliances reported more profound mystical experiences and psychological insights. ?? These findings echo traditional shamanic practices, where the guide plays a central role in fostering emotional and spiritual resonance. Similarly, in modern therapeutic settings, the facilitator’s ability to create a supportive environment enhances the participant’s experience, promoting deeper psychological breakthroughs. ?? Beyond the pharmacological effects of psilocybin, this study highlights the importance of the relational dynamics between facilitators and participants. It suggests that the success of psychedelic therapy depends not just on the substance itself, but on the interpersonal context in which it is administered. Curious to know more? You can read more insights about this study in the #ResearchSummary I have written for Odyssey ! https://lnkd.in/g9wXUmmj

    • 该图片无替代文字

相似主页

查看职位